Hamsters immunized with formalin-inactivated SARS-CoV-2 develop accelerated lung histopathological lesions and Th2-biased response following infection.
de Jong R. et al, (2025), NPJ Vaccines, 10
SARS-CoV-2 infection enhancement by amphotericin B: implications for disease management.
Nguyen D. et al, (2025), J Virol
Longitudinal Immunoprofiling of the CD8+ T-Cell Response in SARS-CoV-2 mRNA Vaccinees and COVID-19 Patients.
Brunetti JE. et al, (2025), Vaccines (Basel), 13
A systems biology approach to define SARS-CoV-2 correlates of protection.
Brady C. et al, (2025), NPJ Vaccines, 10
Complement-mediated enhancement of SARS-CoV-2 antibody neutralisation potency in vaccinated individuals.
Mellors J. et al, (2025), Nat Commun, 16
Detection of mpox and other orthopoxviruses using a lateral flow device as a point-of-care diagnostic.
Laidlaw SM. et al, (2025), Microbiol Spectr
Using minor variant genomes and machine learning to study the genome biology of SARS-CoV-2 over time.
Dong X. et al, (2025), Nucleic Acids Res, 53
Ebola virus persistence: implications for human-to-human transmission and new outbreaks
Meek O. et al, (2025), Exploration of Medicine, 6
Host-pathogen interactions of emerging zoonotic viruses: bats, humans and filoviruses.
Hood G. and Carroll M., (2024), Curr Opin Virol
Therapeutics for Nipah virus disease: a systematic review to support prioritisation of drug candidates for clinical trials.
Chan XHS. et al, (2024), Lancet Microbe
Performance of an envelope glycoprotein-based multiplex immunoassay for Ebola virus antibody detection in a cohort of Ebola virus disease survivors.
Roe MD. et al, (2024), J Virol Methods, 331
Cross reactive responses between filovirus species amongst a cohort of Ebolavirus Zaire survivors in Guinea, West Africa
Jiwa Y. et al, (2024), EUROPEAN JOURNAL OF IMMUNOLOGY, 54, 82 - 82
Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.
Lim YJ. et al, (2024), Br J Haematol, 205, 440 - 451
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.
Goodyear CS. et al, (2024), Lancet Rheumatol, 6, e339 - e351
Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2.
Cornish K. et al, (2024), Open Biol, 14
Serological evidence of zoonotic filovirus exposure among bushmeat hunters in Guinea.
Akoi Boré J. et al, (2024), Nat Commun, 15
Obesity Differs from Diabetes Mellitus in Antibody and T Cell Responses Post COVID-19 Recovery.
Ali M. et al, (2024), Clin Exp Immunol